Ignite Creation Date:
2025-12-25 @ 4:35 AM
Ignite Modification Date:
2025-12-26 @ 3:37 AM
Study NCT ID:
NCT01015118
Status:
COMPLETED
Last Update Posted:
2017-12-07
First Post:
2009-11-09
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-11-17
Start Date Type:
ACTUAL
Primary Completion Date:
2013-04-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-09-15
Completion Date Type:
ACTUAL
First Submit Date:
2009-11-09
First Submit QC Date:
None
Study First Post Date:
2009-11-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-11-14
Results First Submit QC Date:
None
Results First Post Date:
2015-01-15
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2014-04-24
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2017-11-03
Last Update Post Date:
2017-12-07
Last Update Post Date Type:
ACTUAL